BioMS Medical Reaches Milestone in Multiple Sclerosis Trial

Canada’s BioMS Medical has enrolled more than 133 patients in its MAESTRO-03 study, a Phase III trial of MBP8298 for the treatment of secondary progressive multiple sclerosis.

The randomized, double-blind trial will enroll approximately 510 patients who will receive either MBP8298 or placebo intravenously every six months for two years.

Kevin Giese, BioMS’ president and CEO, said he anticipates completing enrollment in the first half of 2008.